BridgeBio Pharma BBIO Reportable Segment — Nonoperating Income (Expense)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's reportable segment — nonoperating income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's reportable segment — nonoperating income (expense)?
- BridgeBio Pharma (BBIO) reported reportable segment — nonoperating income (expense) of -$60.6M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — nonoperating income (expense) changed year-over-year?
- BridgeBio Pharma's reportable segment — nonoperating income (expense) increased by 7.1% year-over-year, from -$65.24M to -$60.6M.
- What does reportable segment — nonoperating income (expense) mean?
- The net total of all income and expenses not related to the company's main business operations.
- How do you interpret reportable segment — nonoperating income (expense)?
- A net positive value indicates the company generates more from non-core activities than it spends, while a negative value indicates a drag on earnings.
- How does reportable segment — nonoperating income (expense) compare across companies?
- Standard financial reporting line item; highly dependent on the company's debt structure and investment portfolio.